Text Size

A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00477425
First received: May 21, 2007
Last updated: December 1, 2010
Last verified: December 2010
History of Changes
  Purpose

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.


Condition Phase
Carcinoma
 Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Resource links provided by NLM:

Drug Information available for: Bevacizumab
U.S. FDA Resources

Further study details as provided by Genentech:

Estimated Enrollment: 150
Study Start Date: June 2007
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Informed Consent Form
  • Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

  • Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • Congenital long QT syndrome
  • Family history of long QT syndrome
  • Clinically significant bradycardia (defined as < 50 beats/minute)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00477425

Sponsors and Collaborators
Genentech
Investigators
Study Director: Jane Huang, M.D. Genentech
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00477425     History of Changes
Other Study ID Numbers: AVF4223g
Study First Received: May 21, 2007
Last Updated: December 1, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech:
Avastin

Additional relevant MeSH terms:
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
 Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013